The British drugmaker, which has its U.S. headquarters just outside Wilmington, said the company saw a 13 percent revenue decline after its cholesterol drug Crestor lost patent protection.
Crestor sales fell over 50 percent to $631 million as generic versions hit the market.
Total revenue is down big from last year, $5.59 billion compared to $6.4 billion.
In a statement, CEO Pascal Soriot said 2017 had the potential to be a turning point for the company as it focuses on rolling out new medicines to battle cancer, metabolic and respiratory diseases.
He said the fourth-quarter drop was expected as AstraZeneca moves away from former blockbuster drugs that are now seeing generic versions flood the market.
The company employs 1,500 hundred people in Delaware at its Fairfax headquarters and Newark packaging facility.
It put its Fairfax campus up for sale in August, but said it is committed to staying in Delaware long-term, by either leasing a portion of that facility back or moving locations within the state.
